Addressing GLP-1 Access Inequity: Lessons from HIV/AIDS Mobilization
The BMJ article by Ratevosian and Sturchio asserts that GLP-1 access inequity is becoming emblematic of global health disparity. This is driven by high costs and limited availability, particularly in low- and middle-income countries. Drawing lessons from the global mobilization that expanded access to HIV antiretroviral therapy (ART), the authors call for urgent, coordinated action. They want to ensure GLP-1 RAs do not remain confined to wealthy populations. Non-communicable diseases (NCDs), including obesity and diabetes, increasingly burden economies and health systems worldwide. This accentuates the need for equitable solutions.
Comparative Analysis of Innovation Access: Lessons from HIV/AIDS Mobilization
The article directly compares the initial lack of ART access for HIV/AIDS and the current disparity in GLP-1 RA availability. Clinical trials have established that GLP-1 RAs, such as semaglutide and tirzepatide, lead to significant and sustained weight loss. They also improve glycemic control and reduce cardiovascular risk for patients with obesity and diabetes. However, with annual costs often exceeding $8,000 per patient in developed markets, access remains elusive for the majority in developing regions. The authors illustrate how global solidarity and policy innovation slashed ART prices by 99%. This brought life-saving treatment to over 31 million people and averted 21 million deaths. Absent similar strategies for GLP-1 RAs, the “innovation access gap” will persist or deepen. This challenge is further intensified as obesity and related NCDs stand as leading causes of death globally. The WHO estimates 2.5 billion overweight adults and economic damages exceeding $4 trillion by 2035.
Innovative Strategies for Market Access and Reimbursement
Collective action in scaling ART benefited from advancements in procurement, supply chains, and community advocacy. This was facilitated by international coalitions like PEPFAR and the Global Fund. For GLP-1 RAs, establishing public-private partnerships could enable the deployment of digital health platforms for prescribing and follow-ups. Such partnerships could also incorporate products into insurance benefit packages and promote voluntary licensing to reduce costs. Reimbursement frameworks must evolve to address the dual burden of obesity and diabetes. The article emphasizes that tackling global inequities requires political will and multisectoral coalitions. Stigma continues to hinder effective prevention and management for obesity. This condition is influenced by environmental, psychosocial, and genetic factors beyond individual choices. As global health leaders prepare for the September 2026 UN High-Level Meeting on NCDs, an unprecedented opportunity arises. This meeting can prioritize financing and innovative delivery strategies for equitable GLP-1 access.
The Path Forward: Opportunities for Change
The article’s parallel to HIV/AIDS is not only historically relevant but also a demonstration that coordinated global action can transform access and outcomes for millions. For Health Economics and Outcomes Research (HEOR) professionals, the challenge lies in supporting evidence-based pricing and reimbursement models. These models must balance affordability with clinical benefit. Options may include outcome-based contracting and international tiered pricing. Ultimately, the trajectory of GLP-1 RAs will hinge on how lessons from ART scale-up are integrated. For insights and a deeper exploration of this vital issue, read the full article here.
